Komori
Share Issuance and Disposal4564OncoTherapy Science,Inc.Pharmaceuticals

Monthly Exercise Status of the 38th Stock Acquisition Rights with Exercise Price Adjustment Clause Issued through a Third-Party Allotment

2026年2月に第38回新株予約権が70,000個行使され、新株7,000,000株が交付された。月末時点の未行使残高は396,000個(39,600,000株)となった。

Worth reading
63In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
7000000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause)

発行・処分する株式数

対象月間の交付株式数:7,000,000株(新株7,000,000株、移転自己株式なし)

Existing Shares and Increase
+2.07%Rate of increase
376,643,700 shares383,643,700Shares

2.07% (exercise ratio relating to exercise restrictions)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
18.6円または19.6円(対象月間の行使状況に記載。修正条項の詳細・下限はNot disclosed)
Number of Stock Acquisition Rights
発行総数:70,000個が発行総数の8.79%。対象月前月末未行使:466,000個、対象月末未行使:396,000個
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
2025年12月8日:第38回新株予約権(行使価額修正条項付)の発行。金額はNot disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalStock acquisition rights issued through a third-party allotment (with exercise price adjustment clause)
Number of shares to be issued or disposed of対象月間の交付株式数:7,000,000株(新株7,000,000株、移転自己株式なし)
Dilution Rate2.07% (exercise ratio relating to exercise restrictions)
Total number of issued shares376,643,700株(対象月の前月末時点) → 383,643,700株(対象月末時点と計算される株数)
Exercise price18.6円または19.6円(対象月間の行使状況に記載。修正条項の詳細・下限はNot disclosed)
Number of Stock Acquisition Rights発行総数:70,000個が発行総数の8.79%。対象月前月末未行使:466,000個、対象月末未行使:396,000個
Procedures under the Corporate Code of ConductThe disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing2025年12月8日:第38回新株予約権(行使価額修正条項付)の発行。金額はNot disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This is a report on the monthly exercise status; no reason for the exercises is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Monthly Exercise Status of the 38th Stock Acquisition Rights with Exercise Price Adjustment Clause Issued through a Third-Party Allotment | OncoTherapy Science,Inc. (4564) timely disclosure | Komori